Cambridge Healthtech Institute’s 3rd Annual

Bispecific Antibody Design

Advances in Engineering and Combination Strategies  

August 25-26, 2020


Bispecific antibodies continue to show significant and impressive therapeutic value with many successes including more than 100 different formats, and about 80 bispecific antibodies are currently in clinical trials. While the development of bispecific antibodies is an evolving field, many challenges are still waiting to be solved by experts in the field including target selection, combination strategies, better understanding of their mechanism of action for rational design, along with reducing off-target toxicity and cytokine release syndromes. CHI’s Third Annual Bispecific Antibody Design conference will delve directly into the technical challenges of bispecific development to improve your candidates’ translatability into the clinic.


Cover will include, but is not limited to:


  • Target selection and engagement
  • Bioassay for bispecific and their mechanism of action
  • Developability assessment along with solutions for manufacturing challenges
  • Engineering of bispecifics, enhancing selectivity for T cell, NK cell and macrophage engagers
  • Different scaffold protein antibody
  • Dual targeting strategies
  • Bispecifics targeting non-checkpoint inhibitor
  • Combination of checkpoints, compare and contrast different combination selection
  • Novel screening technologies to achieve the biology of interest
  • Approaches that reducing off-target toxicities and cytokine release syndromes such as Pro-Drug
  • Regulatory requirements and perspectives


* The program is subject to change without notice, due to unforeseen reason.